Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Report Results
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Fine, Kaplan and Black, R.P.C. Announces Claim Forms Now Being Accepted for Class Action Settlements If You Paid or Reimbursed for Certain Prescription Generic Drugs in the United States Between May 1, 2009 and December 31, 2019

  • USA - Traditional Chinese
  • USA - español
  • USA - Chinese

News provided by

Fine, Kaplan and Black, R.P.C.

Jul 10, 2026, 17:00 ET

Share this article

Share toX

Share this article

Share toX

PHILADELPHIA, July 10, 2026 /PRNewswire/ --

LEGAL NOTICE

If You Paid or Reimbursed for Certain PRESCRIPTION GENERIC DRUGS in the United States between
May 1, 2009 and December 31, 2019, You Could Get a Payment from $533 Million in Class Action
Settlements.

A federal court authorized this Notice.
This is not a solicitation from a lawyer.

1-877-316-0171
www.GenericDrugsEndPayerSettlement.com

You may have seen previous notices about settlements with Sandoz Inc. and Fougera Pharmaceuticals Inc. ("Sandoz"); Apotex Corp. ("Apotex"); Heritage Pharmaceuticals Inc., Emcure Pharmaceuticals, Ltd., and Satish Mehta ("Heritage"); and Sun Pharmaceutical Industries, Inc. ("Sun") and Taro Pharmaceuticals U.S.A., Inc. ("Taro") ("Sun/Taro" for both entities) in the class action lawsuit In re Generic Pharmaceuticals Antitrust Litigation, No. 16-MD-2724 (E.D. Pa.).

The Court has granted final approval of these settlements, and Settlement Class Members may now file a claim to receive settlement benefits. Settlement Class Members do not need to sign up with a claims recovery firm or pay another law firm in order to participate in these settlements.

What is this lawsuit about? This lawsuit claims that generic manufacturers violated federal and state antitrust laws, consumer protection statutes, and common law, causing End-Payers ("EPPs")—including Consumers and Third-Party Payers ("TPPs") (e.g., entities such as insurers or employers with self-funded prescription drug plans)—to pay more than they should have for certain generic drugs ("Named Generic Drugs"). The Settling Defendants and Non-Settling Defendants deny any wrongdoing. The lawsuit remains ongoing against the Non-Settling Defendants.

Who can file a claim for settlement benefits? You can file a claim if you are a member of one or more of the EPP Settlement Classes. The court has certified four EPP Settlement Classes—one for each settlement. You may be a member of one or more of those Settlement Classes if you are a Consumer or TPP that indirectly purchased, paid for, and/or provided reimbursement for some or all of the purchase price for one or more of the Named Generic Drugs, either for personal use by yourself or your members, and other than for resale, in the United States (except Indiana and Ohio) and in some United States territories, at any time during the period from May 1, 2009, through December 31, 2019. Certain kinds of entities are excluded from each Settlement Class. More detailed information, including the full descriptions of each of the four EPP Settlement Classes, and who is or is not included in each Settlement Class; the list of Named Generic Drugs; and how to file a claim, is available at www.GenericDrugsEndPayerSettlement.com (the "EPP Settlement Website").

What do the settlements provide? Sandoz paid $275 million and Sun/Taro paid $200 million to settle all consumer and TPP claims in this lawsuit. Heritage paid $10 million and Apotex paid $48 million to settle the TPP claims in this lawsuit. All Settling Defendants agreed to cooperate with EPPs in providing information related to EPPs' litigation against the Non-Settling Defendants. After deducting settlement notice and administration costs, attorney's fees, litigation expenses, future litigation expenses, and service awards (as applicable), the remaining amounts from each settlement are now available to pay eligible claimants.

How do I get a payment? To receive settlement benefits, you must submit a claim form with supporting documents. You may either complete and submit your claim form online at the EPP Settlement Website on or before November 9, 2026, or you may mail a paper version of your claim form that is postmarked on or before November 9, 2026. You can get a paper version of the claim form through the EPP Settlement Website or call the toll-free number below to have a paper copy of the form mailed to you.

If your claim is valid, you will get a proportional (or pro rata) payment from the Settlement Funds for which you are eligible. Your payment amount will depend on the number of valid claims and the amount of money you spent on the Named Generic Drugs from May 1, 2009 through December 31, 2019.

For more information on how to complete and submit a claim form, visit the EPP Settlement Website or call the toll-free number below. If you do not submit your claim form on or before November 9, 2026, you will not get a payment from the settlements.

For more information: Call 1-877-316-0171 or visit www.GenericDrugsEndPayerSettlement.com.

SOURCE Fine, Kaplan and Black, R.P.C.

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Fine, Kaplan and Black, R.P.C.宣布,若您曾于2009年5月1日至2019年12月31日期间在美国境内支付或报销过特定处方仿制药费用,现可提交集体诉讼和解索赔表

法律声明 若您曾于 2009年5月1日至2019年12月31日期间在美国境内支付或报销过特定处方仿制药费用, 您可能有资格获得集体诉讼和解赔偿金。 本声明经联邦法院授权发布。 本函并非律师发布的委托邀请。 1-877-316-0171...

Fine, Kaplan and Black, R.P.C. anuncia que ya se aceptan formularios de reclamación para los acuerdos de demanda colectiva si pagó o recibió un reembolso por determinados medicamentos genéricos recetados en Estados Unidos entre el 1 de mayo de 2009 y el 31 de diciembre de 2019

AVISO LEGAL Si pagó o recibió un reembolso por determinados MEDICAMENTOS GENÉRICOS RECETADOS en Estados Unidos entre el 1 de mayo de 2009 y el 31 de...

More Releases From This Source

Explore

Pharmaceuticals

Pharmaceuticals

Medical Pharmaceuticals

Medical Pharmaceuticals

Health Care & Hospitals

Health Care & Hospitals

Asian American

Asian American

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2026 Cision US Inc.